| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of this compound is the retinoid receptor pathway. As a structural analogue of retinol (vitamin A), it interacts with retinoic acid receptors to study structure-activity relationships and the molecular basis of retinoid-induced teratogenesis.
|
|---|---|
| ln Vitro |
SRI 6409-94 induces teratogenic effects in vivo, leading to deformed offspring in a dose-dependent manner. It significantly reduces mean fetal body weight and decreases the number of ossified skeletal districts in animal models.
|
| ln Vivo |
In a dose-dependent way, SRI 6409-94 causes virgin female outbred Syrian golden hamciasters to produce malformed offspring[1]. Both the mean fetal body weight and the number of ossified skeletal districts are significantly lower as a result of SRI 6409-94[1].
In vivo studies in virgin female outbred Syrian golden hamsters show that SRI 6409-94 causes deformed offspring in a dose-dependent manner, with significant reductions in mean fetal body weight and in the number of ossified skeletal regions. |
| Enzyme Assay |
Not specified for this compound. General protocols for retinoid binding assays involve competitive binding to retinoic acid receptor (RAR) or retinoid X receptor (RXR) proteins using radiolabeled ligands and filtration techniques.
|
| Cell Assay |
Not specified for this compound. Standard cell-based assays for teratogenicity studies include the embryonic stem cell test (EST) or micromass cultures of embryonic limb bud cells, where changes in differentiation and viability are assessed.
|
| Animal Protocol |
In vivo studies were conducted in virgin female outbred Syrian golden hamsters. Animals were treated with the compound, and the incidence of malformed offspring, fetal body weight, and the number of ossified skeletal regions were evaluated in a dose-dependent manner.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not available for this compound. As an orally active analogue, it is presumed to have suitable oral bioavailability for in vivo studies.
|
| Toxicity/Toxicokinetics |
Toxicological data indicate that SRI 6409-94 exhibits significant teratogenic potential. In hamster models, administration resulted in reduced fetal body weight, decreased skeletal ossification, and the production of deformed offspring.
|
| References |
[1]. Willhite CC, et al. Structure-activity relationships of retinoids in developmental toxicology. IV. Planar Cisoid conformational restriction. Toxicol Appl Pharmacol. 1990 Apr;103(2):324-44.
[2]. Willhite CC, et al. Structure-affinity relationships of retinoids with embryonic cellular retinoic acid-binding protein. Toxicol Appl Pharmacol. 1992 Jan;112(1):144-53. |
| Additional Infomation |
This compound is an orally bioavailable Ro 13-6298 analogue utilized as a molecular tool for studying retinoid teratogenicity. No clinical trials or approved status exist; it is for research use only.
|
| Molecular Formula |
C24H29NO3
|
|---|---|
| Molecular Weight |
379.49
|
| Exact Mass |
379.215
|
| CAS # |
127697-58-9
|
| PubChem CID |
3086620
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.095g/cm3
|
| Boiling Point |
457.4ºC at 760 mmHg
|
| Flash Point |
230.5ºC
|
| Vapour Pressure |
1.49E-08mmHg at 25°C
|
| Index of Refraction |
1.564
|
| LogP |
5.537
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
574
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(C1=CC=C(NC(C2C=CC3C(CCC(C)(C)C=3C=2)(C)C)=O)C=C1)=O
|
| InChi Key |
BACPJFZYTZYCNF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H29NO3/c1-6-28-22(27)16-7-10-18(11-8-16)25-21(26)17-9-12-19-20(15-17)24(4,5)14-13-23(19,2)3/h7-12,15H,6,13-14H2,1-5H3,(H,25,26)
|
| Chemical Name |
ethyl 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (131.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6351 mL | 13.1756 mL | 26.3512 mL | |
| 5 mM | 0.5270 mL | 2.6351 mL | 5.2702 mL | |
| 10 mM | 0.2635 mL | 1.3176 mL | 2.6351 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
